Michael Dalrymple

Title: Michael Dalrymple: Innovator in Biotechnology

Introduction

Michael Dalrymple is a notable inventor based in Dalgety Bay, GB. He has made significant contributions to the field of biotechnology, particularly in the area of human bile salt-stimulated lipase (BSSL). His innovative work has implications for treating various medical conditions.

Latest Patents

Dalrymple holds a patent related to expression methods involving BSSL obtainable from transgenic sheep. The invention encompasses transgenic sheep whose germ cells and somatic cells contain a recombinant nucleotide molecule that encodes human BSSL. Additionally, it outlines methods for producing these transgenic animals and for deriving human BSSL from them. The patent also discusses the use of compositions containing BSSL for treating diseases associated with exocrine pancreatic insufficiency and improving dietary lipid utilization in preterm infants. He has 1 patent to his name.

Career Highlights

Michael Dalrymple is associated with AstraZeneca AB, a leading global biopharmaceutical company. His work at AstraZeneca has allowed him to focus on innovative solutions in healthcare, particularly in the development of therapies that leverage genetic engineering.

Collaborations

Dalrymple has collaborated with notable colleagues, including Lennart Gustav Lundberg and Mats Strömqvist. These partnerships have contributed to advancing research and development in their respective fields.

Conclusion

Michael Dalrymple's contributions to biotechnology, particularly through his patent on BSSL, highlight his role as an innovator in the industry. His work continues to influence the development of treatments for critical health issues.